Journal of Clinical Endocrinology & Metabolism, Vol 65, 30-36, Copyright © 1987 by Endocrine Society

ARTICLES

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

To examine the effects of age and duration and treatment of insulin- dependent diabetes (IDDM) on residual beta-cell function, we measured the fasting and Sustacal-stimulated serum C-peptide levels in 610 conventionally treated IDDM patients (age, 13-39 yr; duration of diabetes, 1-15 yr) during eligibility screening for the Diabetes Control and Complications Trial (DCCT). Fasting and stimulated C- peptide values were closely correlated (r = 0.83; P less than 0.001), and both declined with increasing duration of disease. However, among patients who had been diabetic for more than 5 yr, 11% (33 of 296) of adults compared with 0 of 75 adolescents (P less than 0.001) retained substantial insulin secretory capacity. Patients with stimulated C- peptide levels greater than 0.2 pmol/mL had a significantly lower mean fasting plasma glucose level [177 +/- 6 (+/- SEM) vs. 222 +/- 6 mg/dL; P less than 0.001), a smaller rise in glucose after Sustacal administration (151 +/- 5 vs. 184 +/- 3 mg/dL; P less than 0.001), and lower hemoglobin A1C (8.4 +/- 0.2% vs. 9.3 +/- 0.1%; P less than 0.001) than the patients with a stimulated C-peptide level of 0.05 pmol/mL or less, even though the C-peptide secretors were receiving less insulin (0.52 +/- 0.02 vs. 0.78 +/- 0.02 U/kg X day; P less than 0.001). To determine the effects of treatment of beta-cell function, 33 patients with stimulated C-peptide values between 0.2 and 0.5 pmol/mL at entry in the DCCT were restudied 1 yr after randomization to standard treatment (n = 15) or an experimental (n = 18) treatment designed to achieve and maintain near-normal glucose levels. Although C-peptide levels declined in both groups, experimental treatment was associated with slightly less of a decline in stimulated C-peptide values compared to Standard treatment. The results of C-peptide measurements in this large and well defined population of IDDM patients demonstrate that residual beta-cell function continues for a longer period of time in adults compared to adolescents with IDDM. This endogenous insulin secretion contributes significantly to metabolic control and may be prolonged by intensive insulin treatment regimens.

This article has been cited by other articles:

				A. Rewers, G. Klingensmith, C. Davis, D. B. Petitti, C. Pihoker, B. Rodriguez, I. D. Schwartz, G. Imperatore, D. Williams, L. M. Dolan, et al. Presence of Diabetic Ketoacidosis at Diagnosis of Diabetes Mellitus in Youth: The Search for Diabetes in Youth Study Pediatrics, May 1, 2008; 121(5): e1258 - e1266. [Abstract] [Full Text] [PDF]

				S. Porksen, L. B. Nielsen, A. Kaas, M. Kocova, F. Chiarelli, C. Orskov, J. J. Holst, K. B. Ploug, P. Hougaard, L. Hansen, et al. Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2910 - 2916. [Abstract] [Full Text] [PDF]

				R. B. Lipton Incidence of Diabetes in Children and Youth--Tracking a Moving Target JAMA, June 27, 2007; 297(24): 2760 - 2762. [Full Text] [PDF]

				L. B Nielsen, K. B Ploug, P. Swift, C. Orskov, I. Jansen-Olesen, F. Chiarelli, J. J Holst, P. Hougaard, S. Porksen, R. Holl, et al. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes Eur. J. Endocrinol., June 1, 2007; 156(6): 663 - 671. [Abstract] [Full Text] [PDF]

				R. Mallone, E. Martinuzzi, P. Blancou, G. Novelli, G. Afonso, M. Dolz, G. Bruno, L. Chaillous, L. Chatenoud, J.-M. Bach, et al. CD8+ T-Cell Responses Identify {beta}-Cell Autoimmunity in Human Type 1 Diabetes Diabetes, March 1, 2007; 56(3): 613 - 621. [Abstract] [Full Text] [PDF]

				N. A. Sherry, J. A. Kushner, M. Glandt, T. Kitamura, A.-M. B. Brillantes, and K. C. Herold Effects of Autoimmunity and Immune Therapy on {beta}-Cell Turnover in Type 1 Diabetes Diabetes, December 1, 2006; 55(12): 3238 - 3245. [Abstract] [Full Text] [PDF]

				A. Samann, I. Muhlhauser, R. Bender, W. Hunger-Dathe, C. Kloos, and U. A. Muller Flexible Intensive Insulin Therapy in Adults With Type 1 Diabetes and High Risk for Severe Hypoglycemia and Diabetic Ketoacidosis Diabetes Care, October 1, 2006; 29(10): 2196 - 2199. [Abstract] [Full Text] [PDF]

				K. Nakanishi and H. Inoko Combination of HLA-A24, -DQA1*03, and -DR9 Contributes to Acute-Onset and Early Complete {beta}-Cell Destruction in Type 1 Diabetes: Longitudinal Study of Residual {beta}-Cell Function Diabetes, June 1, 2006; 55(6): 1862 - 1868. [Abstract] [Full Text] [PDF]

				R. D. G. Leslie, R. Williams, and P. Pozzilli Type 1 Diabetes and Latent Autoimmune Diabetes in Adults: One End of the Rainbow J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1654 - 1659. [Abstract] [Full Text] [PDF]

				K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes Diabetes, June 1, 2005; 54(6): 1763 - 1769. [Abstract] [Full Text] [PDF]

				G. Bruno, F. Cerutti, F. Merletti, P. Cavallo-Perin, E. Gandolfo, M. Rivetti, C. Runzo, S. Pinach, G. Pagano, and The Piedmont Study Group for Diabetes Epidemiology Residual {beta}-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in Children: The registry of type 1 diabetes of the province of Turin, Italy, 1984-2000 Diabetes Care, February 1, 2005; 28(2): 312 - 317. [Abstract] [Full Text] [PDF]

				R. D. G. Leslie and M. D. Castelli Age-Dependent Influences on the Origins of Autoimmune Diabetes: Evidence and Implications Diabetes, December 1, 2004; 53(12): 3033 - 3040. [Full Text] [PDF]

				E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]

				C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				G. S. EISENBARTH Insulin Autoimmunity: Immunogenetics/Immunopathogenesis of Type 1A Diabetes Ann. N.Y. Acad. Sci., November 1, 2003; 1005(1): 109 - 118. [Abstract] [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				M. W. Steffes, S. Sibley, M. Jackson, and W. Thomas {beta}-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial Diabetes Care, March 1, 2003; 26(3): 832 - 836. [Abstract] [Full Text] [PDF]

				K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, et al. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1692 - 1698. [Abstract] [Full Text] [PDF]

				J. P. PALMER Beta Cell Rest and Recovery--Does It Bring Patients with Latent Autoimmune Diabetes in Adults to Euglycemia? Ann. N.Y. Acad. Sci., April 1, 2002; 958(1): 89 - 98. [Abstract] [Full Text] [PDF]

				L. Zhang, G. Krzentowski, A. Albert, and P. J. Lefebvre Risk of Developing Retinopathy in Diabetes Control and Complications Trial Type 1 Diabetic Patients With Good or Poor Metabolic Control Diabetes Care, July 1, 2001; 24(7): 1275 - 1279. [Abstract] [Full Text] [PDF]

				Effect of Intensive Therapy on Residual {beta}-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial: A Randomized, Controlled Trial Ann Intern Med, April 1, 1998; 128(7): 517 - 523. [Abstract] [Full Text]

				H. P. Chase, K. R. Crews, S. Garg, M. J. Crews, K. J. Cruickshanks, G. Klingensmith, E. Gay, and R. F. Hamman (Outpatient Management vs In-Hospital Management of Children with New-Onset Diabetes Clinical Pediatrics, August 1, 1992; 31(8): 450 - 456. [Abstract] [PDF]